Antiplatelet therapy in the management of cardiovascular disease in patients with CKD: What is the evidence?

Clinical Journal of the American Society of Nephrology

Volumn 8, Issue 4, 2013, Pages 665-674

  Jain, Nishank ^a   Susan Hedayati, S ^a   Sarode, Ravindra ^b   Banerjee, Subhash ^b,c   Reilly, Robert F ^a  

^a VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; DESMOPRESSIN; DIPYRIDAMOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PRASUGREL; TICAGRELOR;

BLEEDING; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; HYPERURICEMIA; LOADING DRUG DOSE; LOW DRUG DOSE; META ANALYSIS (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOCYTE DYSFUNCTION; UREMIA;

EID: 84878913798     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.06790712     Document Type: Review

References (68)

1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA 298: 2038-2047, 2007
2. Machecourt J, Danchin N, LablancheJM, Fauvel JM, Bonnet JL, MarliereS, Foote A, Quesada JL, Eltchaninoff H, Vanzetto G; EVASTENT Investigators: Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: The EVASTENT Matched-Cohort Registry. J Am Coll Cardiol 50: 501-508, 2007
3. Best PJ, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR, Berger PB: The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 39: 1113-1119, 2002
4. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, IkizlerTA, HimmelfarbJ: Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 65: 1009-1016, 2004
5. Boccardo P, Remuzzi G, Galbusera M: Platelet dysfunction in renal failure. Semin Thromb Hemost30: 579-589, 2004
6. Leblond F, Guevin C, Demers C, Pellerin I, Gascon-Barre M, Pichette V: Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol 12: 326-332, 2001
7. Muntner P, He J, Astor BC, Folsom AR, Coresh J: Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: Results from the atherosclerosis risk in communities study. J Am Soc Nephrol 16: 529-538, 2005
8. Debella YT, Giduma HD, Light RP, Agarwal R: Chronic kidney disease as a coronary disease equivalent-a comparison with diabetes over a decade. Clin J Am Soc Nephrol 6: 1385-1392, 2011
9. Peterson PN, Rumsfeld JS, Liang L, Hernandez AF, Peterson ED, Fonarow GC, Masoudi FA; American Heart Association Get With The Guidelines-Heart Failure Program: Treatment and risk in heart failure: Gaps in evidence or quality? Circ Cardiovasc Qual Outcomes 3: 309-315, 2010
10. Fox CS, Muntner P, Chen AY, Alexander KP, Roe MT, Cannon CP, Saucedo JF, Kontos MC, Wiviott SD;Acute Coronary Treatment and Intervention Outcomes Network registry: Use of evidence- based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: A report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation 121: 357-365, 2010
11. Holden RM, Harman GJ, Wang M, Holland D, Day AG: Major bleeding in hemodialysis patients. Clin J Am Soc Nephrol 3:105-110, 2008
12. Kozek-Langenecker SA, Masaki T, Mohammad H, Green W, Mohammad SF, Cheung AK: Fibrinogen fragments and platelet dysfunction in uremia. Kidney Int 56: 299-305, 1999
13. SloandJA, Sloand EM: Studies on platelet membrane glycoproteins and platelet function during hemodialysis. J Am Soc Nephrol 8: 799-803, 1997
14. Landray MJ, Wheeler DC, Lip GYH, Newman DJ, Blann AD, McGlynn FJ, Ball S, Townend JN, Baigent C: Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: The chronic renal impairment in Birmingham (CRIB) study. Am J Kid Dis 43: 244-253, 2004
15. Spiel AO, Gilbert JC, Jilma B: von Willebrand factor in cardiovascular disease: Focus on acute coronary syndromes. Circulation 117: 1449-1459, 2008
16. Kaufmann JE, Vischer UM: Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost 1: 682-689, 2003
17. Sica DA, GehrTW: Desmopressin: Safety considerations in patients with chronic renal disease. Drug Saf29: 553-556, 2006
18. Moncada S, Korbut R: Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet 1: 1286-1289, 1978
19. FitzGerald GA: Dipyridamole. N EnglJ Med316:1247-1257,1987
20. Goto S: Cilostazol: Potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler Suppl 6: 3-11, 2005
21. Mullangi R, Srinivas NR: Clopidogrel: Review of bioanalytical methods, pharmacokinetics/pharmacodynamics, and update on recent trends in drug-drug interaction studies. Biomed Chromatogr23: 26-41, 2009
22. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann F-J, Ardissino D, De Servi S, Murphy SA, RiesmeyerJ, Weerakkody G, Gibson CM, Antman EM; TRITON- TIMI 38 Investigators: Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357: 2001-201 5, 2007
23. James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, Harrington RA, Horrow J, Katus H, Keltai M, Lewis BS, Parikh K, Storey RF, Szummer K, Wojdyla D, Wallentin L: Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: Results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 122: 1056-1067, 2010
24. Gaglia MAJr, Waksman R: Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding ticagrelor. Circulation 123: 451-456, 2011
25. Baigent C, Landray M, Leaper C, Altmann P, Armitage J, Baxter A, Cairns HS, Collins R, Foley RN, Frighi V, Kourellias K, Ratcliffe PJ, Rogerson M, Scoble JE, Tomson CR, Warwick G, Wheeler DC: First United Kingdom Heart and Renal Protection (UK-HARP-I) study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis 45: 473-484, 2005
26. Ethier J, Bragg-Gresham JL, Piera L, Akizawa T, Asano Y, Mason N, Gillespie BW, Young EW: Aspirin prescription and outcomes in hemodialysis patients: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 50: 602-611, 2007
27. Sciahbasi A, Arcieri R, Quarto M, Pendenza G, Lanzillo C, Summaria F, Romagnoli E, Commisso C, Penco M, Lioy E: Impact of chronic aspirin and statin therapy on presentation of patients with acute myocardial infarction and impaired renal function. Prev Cardiol 13:18-22, 2010
28. Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F, Copetti M, Graziano G, Tognoni G, Jardine M, Webster A, Nicolucci A, Zoungas S, Strippoli GF: Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: A systematic review and meta-analysis. Ann Intern Med 156: 445-459, 2012
29. Dasgupta A, Steinhubl SR, Bhatt DL, Berger PB, Shao M, MakK H, Fox KAA, Montalescot G, Weber MA, Haffner SM, Dimas AP, Steg PG, Topol EJ; CHARISMA Investigators: Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high 626-1atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). Am J Cardiol 103: 1359-1363, 2009
30. Keltai M, Tonelli M, MannJ F, Sitkei E, Lewis BS, Hawken S, Mehta SR, Yusuf S;CURE Trial Investigators: Renal function and outcomes in acute coronary syndrome: Impact of clopidogrel. Eur J Cardiovasc Prev Rehabil 14:312-318, 2007
31. Basra SS, Tsai P, Lakkis NM: Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease. J Am Coll Cardiol 58: 2263-2269, 2011
32. Best PJM, Steinhubl SR, Berger PB, Dasgupta A, Brennan DM, Szczech LA, Califf RM, Topol EJ; CREDO Investigators: The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: Results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J 155: 687-693, 2008
33. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E;PRINCIPLE-TIMI 44 Investigators: Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 11 6: 2923-2932, 2007
34. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, Goodman SG, Corbalan R, Purdy DA, Murphy SA, McCabe CH, Antman EM; TRITON-TIMI 38 Investigators: Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 118: 1626-1636, 2008
35. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, Halperin J, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Schwamm LH, Tomsick T; American Heart Association/American Stroke Association Council on StrokeCouncil on Cardiovascular Radiology and InterventionAmerican Academy of Neurology: Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: A statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: Co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation 113: e409-e449, 2006
36. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345: 494-502, 2001
37. Woo J S, Kim W, Lee SR, Jung KH, Kim WS, Lew J H, Lee TW, Lim CK: Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: Results of the effect of platelet inhibition according to clopidogrel dose in patients with chronic kidney disease (PIANO-2 CKD) randomized study. Am Heart J 162: 1018-1025, 2011
38. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A;ESPRIT Study Group: Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): Randomised controlled trial. Lancet 367: 1665-1673, 2006
39. Aradi D, Komocsi A, Vorobcsuk A, Rideg O, Tokes-Fuzesi M, Magyarlaki T, Horvath IG, Serebruany VL: Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: Systematic review and meta-analysis. Am Heart J 160: 543-551, 2010
40. Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, Moschi G, Gori AM, Abbate R, Antoniucci D: Impact of platelet reactivity after clopidogrel administration on drug- eluting stent thrombosis. J Am Coll Cardiol 49: 2312-2317, 2007
41. Frere C, Cuisset T, Quilici J, Camoin L, Carvajal J, Morange PE, Lambert M, Juhan-Vague I, Bonnet JL, Alessi MC: ADP-induced platelet aggregation and platelet reactivity index VASPare good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost 98: 838-843, 2007
42. Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK, Gesheff T, Chaganti SK, Etherington A, Tantry US: Evaluation of dose-related effects of aspirin on platelet function: Results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 115: 3156-3164, 2007
43. Nguyen TA, DiodatiJG, Pharand C: Resistance to clopidogrel: A review of the evidence. J Am Coll Cardiol 45: 1157-1164, 2005
44. Angiolillo DJ, Bernardo E, Capodanno D, Vivas D, Sabate M, Ferreiro JL, Ueno M, Jimenez-Quevedo P, Alfonso F, Bass TA, Macaya C, Fernandez-Ortiz A: Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol 55: 1139-1146, 2010
45. Htun P, Fateh-Moghadam S, Bischofs C, Banya W, Muller K, Bigalke B, Stellos K, MayAE, FlatherM, Gawaz M, GeislerT: Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention. J Am Soc Nephrol 22: 627633, 2011
46. Morel O, El Ghannudi S, Jesel L, Radulescu B, Meyer N, Wiesel ML, Caillard S, Campia U, Moulin B, Gachet C, Ohlmann P: Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel. J Am Coll Cardiol 57: 399-408, 2011
47. Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, Ikeda T, Kurihara A: Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. DrugMetab Dispos 38: 92-99, 2010
48. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS: Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360: 354-362, 2009
49. Nolin TD, Frye RF, Le P, Sadr H, Naud J, Leblond FA, Pichette V, Hi mmelfarbJ: ESRD impairs nonrenal clearanceof fexofenadine but not midazolam. J Am Soc Nephrol20: 2269-2276, 2009
50. Dreisbach AW: The influence of chronic renal failure on drug metabolism and transport. Clin Pharmacol Ther86: 553-556, 2009
51. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, Klag MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS, Pfeffer MA, Wenger NK, Wilson PW, Wright JT Jr: Controllingthe epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 32: 853-906, 1998
52. Kasiske BL, Zeier MG, Chapman JR, Craig JC, Ekberg H, Garvey CA, Green MD, Jha V, Josephson MA, Kiberd BA, Kreis HA, McDonald RA, Newmann JM, Obrador GT, Vincenti FG, Cheung M, Earley A, Raman G, Abariga S, Wagner M, Balk EM; Kidney Disease: Improving Global Outcomes: KDIGO clinical practice guideline for the care of kidney transplant recipients: A summary. Kidney Int 77: 299-311, 2010
53. Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, Fesmire FM, Ganiats TG, Jneid H, Lincoff AM, Peterson ED, Philippides GJ, Theroux P, Wenger NK, Zidar JP, Jacobs AK: 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non-ST- Elevation Myocardial Infarction (Updating the 2007 Guideline): A report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. Circulation 123: 2022-2060, 2011
54. Wolff T, Miller T, Ko S: Aspirin for the primary prevention of cardiovascular events: An update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 150: 405-410, 2009
55. Budnitz DS, Lovegrove MC, Shehab N, Richards CL: Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 365:2002-2012, 2011
56. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr; 2011 WRITING GROUP MEMBERSACCF/AHA TASK FORCE MEMBERS: 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 123: e426-e579, 2011
57. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM, Hong Y, Miller NH, Lauer RM, Ockene IS, Sacco RL, SallisJF Jr, Smith SC Jr, Stone NJ, Taubert KA; American Heart Association Science Advisory and Coordinating Committee: AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. Circulation 106: 388-391, 2002
58. Smith SC Jr, Feldman TE, HirshfeldJWJr, Jacobs AK, Kern MJ,King SB 3rd, Morrison DA, O'Neil WW, Schaff HV, Whitlow PL, Williams DO, Antman EM, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 113: e1 66-e286, 2006
59. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, van der Heyden JA, Rensing BJ, Suttorp MJ, Hackeng CM, ten Berg JM: Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA303: 754-762, 2010
60. Serebruany V, Cherala G, Williams C, Surigin S, Booze C, Kuliczkowski W, Atar D: Association of platelet responsiveness with clopidogrel metabolism: Role of compliance in the assessment of resistance. Am Heart J 158: 925-932, 2009
61. Becker DM, Segal J, Vaidya D, Yanek LR, Herrera-Galeano JE, Bray PF, Moy TF, Becker LC, Faraday N: Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA 295: 1420-1427, 2006
62. Bordeaux BC, Qayyum R, Yanek LR, Vaidya D, Becker LC, Faraday N, Becker DM: Effect of obesity on platelet reactivity and response to low-dose aspirin. Prev Cardiol 13: 56-62, 2010
63. DiChiara J, Bliden KP, Tantry US, Hamed MS, Antonino MJ, Suarez TA, Bailon O, Singla A, Gurbel PA: The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: An analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes 56: 3014-301 9, 2007
64. Dyszkiewicz-Korpanty AM, Frenkel EP, Sarode R: Approach to the assessment of platelet function: Comparison between optical- based platelet-rich plasma and impedance-based whole blood platelet aggregation methods. Clin Appl Thromb Hemost 11: 25 2005
65. Sun B, Le SN, Lin S, Fong M, Guertin M, Liu Y, Tandon NN, Yoshitake M, Kambayashi J: New mechanism of action for cilostazol: Interplay between adenosine and cilostazol in inhibiting platelet activation. J Cardiovasc Pharmacol 40: 577585, 2002
66. Bhatt DL: Antiplatelet therapy: Ticagrelor in ACS-what does PLATO teach us? Nat Rev Cardiol 6: 737-738, 2009
67. Farid NA, Kurihara A, Wrighton SA: Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol 50: 126-142, 2010
68. Micromedex 2.0 (Healthcare Series). Version 5.1., Greenwood Village, CO, Thomson Reuters Healthcare Published online ahead of print. Publication date available at www.cjasn.org.